Is Chronic Kidney Disease The Same As Kidney Failure

No. Chronic kidney disease (CKD) is a long-term spectrum of kidney damage or reduced function lasting at least 3 months, while kidney failure is the most severe end of that spectrum (Stage G5/ESKD) when filtration falls below about 15 mL/min/1.73 m² or dialysis/transplant is needed—so kidney failure is a subset of CKD, not a separate condition. This distinction comes directly from KDIGO 2024’s CGA classification system, which defines CKD and labels G5 as “kidney failure.”

Why the terms get mixed up?

People often use “CKD” and “kidney failure” interchangeably because the final stage of CKD is literally called kidney failure, but medically they describe different points on the same continuum of disease. Early CKD can exist with normal or mildly reduced eGFR if albuminuria or structural abnormalities persist for 3+ months, whereas kidney failure implies severe loss of function and often renal replacement therapy.

Formal definitions clinicians use

• CKD: Abnormalities of kidney structure or function for at least 3 months, with health implications; staged by Cause, GFR (G1–G5), and Albuminuria (A1–A3)—the CGA system (KDIGO 2024).
• Kidney failure: GFR category G5 (<15 mL/min/1.73 m²) and/or treatment with dialysis or a kidney transplant; also termed end-stage kidney disease (ESKD).

According to research by the KDIGO 2024 Guideline Work Group (Kidney International Supplement, March–April 2024), the CGA framework standardizes language globally and aligns management intensity with risk across stages.

Stages of chronic kidney disease versus failure

• G1–G2: eGFR ≥60 with persistent markers of kidney damage (e.g., albuminuria) for ≥3 months.
• G3a–G3b: eGFR 30–59; complications such as anemia and bone-mineral disorders may emerge, increasing risk of progression.
• G4: eGFR 15–29; preparation for renal replacement therapy commonly begins.
• G5: eGFR <15 or dialysis/transplant; referred to as kidney failure/ESKD.

According to the National Kidney Foundation (updated May 23, 2025), Stage 5 CKD “means you have kidney failure,” usually requiring dialysis or transplant planning.

Albuminuria matters as much as eGFR

CKD severity is not graded by filtration alone. KDIGO 2024 emphasizes albuminuria categories (A1–A3) alongside GFR because higher urine albumin strongly predicts faster progression to kidney failure and cardiovascular events. In practice, the combined GFR-albuminuria grid stratifies risk from low to very high and guides how often to monitor and when to escalate care.

According to research summarized by Iatridi and colleagues (KDIGO 2024 guideline synthesis, September 18, 2024), monitoring eGFR and uACR should occur at least annually—and more often in higher-risk CGA categories—to detect progression early.

How CKD is diagnosed early (before failure)

• Confirm chronicity: Repeat eGFR and albuminuria after 3 months to confirm persistent abnormality and exclude acute kidney injury.
• Use CGA staging: Identify cause, align GFR stage with albuminuria category, and apply risk tools like the Kidney Failure Risk Equation (KFRE) in G3–G5.
• Track change thresholds: A >20% drop in eGFR or a doubling of uACR exceeds usual variability and warrants evaluation, per KDIGO 2024.

According to KDIGO 2024 recommendations (Executive Summary, 2024), risk-based monitoring and early intervention slow progression and optimize timing for referrals.

What “kidney failure” means clinically

Kidney failure indicates inadequate kidney function to maintain fluid, electrolyte, and toxin balance, typically at eGFR <15, producing uremic symptoms and complications such as volume overload, hyperkalemia, metabolic acidosis, and anemia. Treatment options are hemodialysis, peritoneal dialysis, kidney transplant, or conservative care according to goals and comorbidities.

According to the UK Kidney Association’s staging resource, Stage G5 (often termed end-stage renal failure) is when kidney function is insufficient and renal replacement therapies or transplant may be required.

Managing CKD to prevent failure

• Blood pressure and RAAS blockade: Foundation of slowing CKD progression, integrated into KDIGO 2024 updates.
• SGLT2 inhibitors and finerenone: Evidence supports use in proteinuric CKD (with or without diabetes) to reduce progression risk.
• Lipid and CV risk management: Statins and CV risk equations that incorporate eGFR and albuminuria are emphasized.
• Nephrotoxin stewardship and sick-day rules: Education to avoid AKI episodes that accelerate decline.

According to research by Awdishu et al. (AJHP, June 10, 2025), KDIGO 2024 highlights comprehensive pharmacologic and safety strategies to delay CKD progression and reduce complications.

Conclusion and next steps with Dr. Vishal Golay

CKD and kidney failure are related but not the same—CKD is any chronic abnormality of kidney structure or function over 3 months, and kidney failure is the most advanced stage requiring dialysis or transplant in most cases. Knowing the CGA stage and risk enables proactive therapy to delay or avoid kidney failure.

For personalized care in Siliguri, West Bengal, Dr. Vishal Golay’s nephrology service offers:

• Comprehensive CGA staging with eGFR and uACR, plus KFRE-based risk estimation to plan follow-up and interventions.
• Evidence-based treatment optimization, including RAAS blockade, SGLT2 inhibitors, finerenone when appropriate, and cardiovascular risk management.
• Timely preparation for dialysis modalities and transplant referral when risk thresholds or eGFR criteria are met, with education tailored to goals and lifestyle.

According to research by the KDIGO 2024 Work Group (Kidney International Supplement, 2024) and the National Kidney Foundation (2025), early staging, albuminuria monitoring, and risk-guided care are central to preventing progression to kidney failure.